| Ytd | 41.91% | |
| 1y | 55.22% |
| Open | 16.90 | Prev Close | 17.05 | Low | 15.99 | High | 17.02 | Mkt Cap | 610.40M |
| Vol | 146.92K | Avg Vol | 430.60K | EPS | -1.72 | P/E | N/A | Forward P/E | -7.68 |
| Beta | 0.74 | Short Ratio | 13.66 | Inst. Own | 72.39% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-29 | 50-d Avg | 14.90 | 200-d Avg | 13.36 | 1yr Est | 29.25 |
CTNM News
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),
Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's
RBC Capital analyst Brian Abrahams maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperfo
Contineum has streamlined its discovery programs to focus on drug candidates for the treatment of in
Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.40) per share which beat the a
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),
Does Contineum Therapeutics, Inc. (CTNM) have what it takes to be a top stock pick for momentum inve
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmace
- Manuscript describes the discovery of LPAR1 antagonist PIPE-791, now in a Phase 2 clinical trial f
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),
The consensus price target hints at a 60% upside potential for Contineum Therapeutics, Inc. (CTNM).
Contineum Therapeutics NASDAQ: CTNM President and Chief Executive Officer Carmine Stengone said the
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),
Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Equal-W
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),
The average of price targets set by Wall Street analysts indicates a potential upside of 49.2% in Co
Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.39) per share which beat the a
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),
Contineum stock rises after PIPE-791 pain trial shows safety and early efficacy signals, with mixed
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmace
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),
Contineum Therapeutics, Inc. (NASDAQ: CTNM - Get Free Report) has been given a consensus recommendat
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),
Baird analyst Joel Beatty maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and ra
Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.49) per share which beat the a
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),
Morgan Stanley analyst Jeffrey Hung downgrades Contineum Therapeutics (NASDAQ:CTNM) from Overweig
Baird analyst Joel Beatty maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and lo
Contineum's Multiple Sclerosis drug missed key goals in a Phase 2 trial as RBC cut its target bu
RBC Capital analyst Brian Abrahams maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperfo
CTNM: -20% | Contineum Therapeutics shares are trading lower after the company announced that toplin
